{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T22:31:03Z","timestamp":1793313063542,"version":"4.5.0"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,5,21]],"date-time":"2024-05-21T00:00:00Z","timestamp":1716249600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,5,21]],"date-time":"2024-05-21T00:00:00Z","timestamp":1716249600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Invasive cutaneous squamous cell carcinomas (cSCC) are a leading cause of death in recessive dystrophic epidermolysis bullosa (RDEB), a rare blistering genodermatosis. Outcomes of RDEB-cSCC therapies have primarily been described in case reports. Systematic studies are scarce. This systematic review aims to assess the pathophysiology, clinical characteristics, and outcomes of RDEB-cSCCs, with a focus on results and mechanisms of recent immunotherapies and anti-EGFR treatments.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A systematic literature search of epidermolysis bullosa and cSCC was performed in February 2024, using PubMed, Embase, Cochrane Central Register of Controlled Trials, ClinicalTrials.gov, and EudraCT databases. Cases with administration of systematic therapies and unpublished outcomes regarding death were tracked with corresponding authors. Data extraction and risk of bias assessment was performed by two independent reviewers. Of 1132 references in the original search, 163 relevant articles were identified, representing 59 case reports, 7 cohort studies, 49 abstracts, 47 in-vitro\/in-vivo experiments, and 1 bioinformatic study. From these, 157 cases of RDEB-cSCCs were included. The majority of RDEB-cSCCs were well-differentiated (64.1%), ulcerated (59.6%), and at least 2\u00a0cm in size (77.6%), with a median age at diagnosis of 30\u00a0years old (range 6\u201368.4). Surgery was the primary form of treatment (<jats:italic>n<\/jats:italic>\u2009=\u2009128), followed by chemotherapy and radiotherapy. Anti-EGFR therapy and immunotherapy was also reported beginning in 2009 and 2019, respectively. Survival time from first cSCC diagnosis to death was available in 50 cases. When stratified by their treatment regimen, median survival time was 1.85\u00a0years (surgery\u2009+\u2009chemotherapy, <jats:italic>n<\/jats:italic>\u2009=\u20096), 2\u00a0years (surgery only, <jats:italic>n<\/jats:italic>\u2009=\u200919), 4.0\u00a0years (+\u2009anti-EFGR therapy, <jats:italic>n<\/jats:italic>\u2009=\u200910), 4\u00a0years (surgery\u2009+\u2009radiotherapy, n\u2009=\u20099), 4.6\u00a0years (+\u2009immunotherapy, <jats:italic>n\u2009=\u2009<\/jats:italic>4), and 9.5\u00a0years (surgery\u2009+\u2009chemotherapy\u2009+\u2009radiotherapy; <jats:italic>n\u2009=\u2009<\/jats:italic>2). Treatment-related adverse events were primarily limited to impaired wound healing for immunotherapies and nausea and fatigue for anti-EGFR therapies.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Despite the challenges of a limited sample size in a rare disease, this systematic review provides an overview of treatment options for cSCCs in RDEB. When surgical treatment options have been exhausted, the addition of immunotherapy and\/or anti-EGFR therapies may extend patient survival. However, it is difficult to attribute extended survival to any single treatment, as multiple therapeutic modalities are often used to treat RDEB-cSCCs.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13023-024-03190-1","type":"journal-article","created":{"date-parts":[[2024,5,21]],"date-time":"2024-05-21T02:01:44Z","timestamp":1716256904000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Therapies for cutaneous squamous cell carcinoma in recessive dystrophic epidermolysis bullosa: a systematic review of 157 cases"],"prefix":"10.1186","volume":"19","author":[{"given":"Austin","family":"Hwang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andie","family":"Kwon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corinne H.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonia","family":"Reimer-Taschenbrecker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6187-6549","authenticated-orcid":false,"given":"Amy S.","family":"Paller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,21]]},"reference":[{"issue":"4","key":"3190_CR1","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1111\/bjd.18921","volume":"183","author":"C Has","year":"2020","unstructured":"Has C, Bauer JW, Bodemer C, Bolling MC, Bruckner-Tuderman L, Diem A, et al. Consensus reclassification of inherited epidermolysis bullosa and other disorders with skin fragility. Br J Dermatol. 2020;183(4):614\u201327.","journal-title":"Br J Dermatol"},{"issue":"2","key":"3190_CR2","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.jaad.2008.09.035","volume":"60","author":"J-D Fine","year":"2009","unstructured":"Fine J-D, Johnson LB, Weiner M, Li K-P, Suchindran C. Epidermolysis bullosa and the risk of life-threatening cancers: the National EB Registry experience, 1986\u20132006. J Am Acad Dermatol. 2009;60(2):203\u201311.","journal-title":"J Am Acad Dermatol"},{"key":"3190_CR3","doi-asserted-by":"publisher","unstructured":"Cho RJ, Alexandrov LB, den Breems NY, Atanasova VS, Farshchian M, Purdom E, et al. APOBEC mutation drives early-onset squamous cell carcinomas in recessive dystrophic epidermolysis bullosa. Sci Transl Med. 2018; https:\/\/doi.org\/10.1126\/scitranslmed.aas9668.","DOI":"10.1126\/scitranslmed.aas9668"},{"key":"3190_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.matbio.2017.01.002","volume":"63","author":"L Guerra","year":"2017","unstructured":"Guerra L, Odorisio T, Zambruno G, Castiglia D. Stromal microenvironment in type VII collagen-deficient skin: The ground for squamous cell carcinoma development. Matrix Biol. 2017;63:1\u201310.","journal-title":"Matrix Biol"},{"issue":"5","key":"3190_CR5","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1111\/exd.14304","volume":"30","author":"K Twaroski","year":"2021","unstructured":"Twaroski K, Chen W, Pickett-Leonard M, Tolar J. Role of transforming growth factor-\u03b21 in recessive dystrophic epidermolysis bullosa squamous cell carcinoma. Exp Dermatol. 2021;30(5):664\u201375.","journal-title":"Exp Dermatol"},{"issue":"1","key":"3190_CR6","doi-asserted-by":"publisher","first-page":"70","DOI":"10.2340\/00015555-2781","volume":"98","author":"M Kim","year":"2018","unstructured":"Kim M, Li M, Intong-Wheeler LRA, Tran K, Marucci D, Murrell DF. Epidemiology and Outcome of Squamous Cell Carcinoma in Epidermolysis Bullosa in Australia and New Zealand. Acta Derm Venereol. 2018;98(1):70\u20136.","journal-title":"Acta Derm Venereol"},{"issue":"1","key":"3190_CR7","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1111\/bjd.14104","volume":"174","author":"JE Mellerio","year":"2016","unstructured":"Mellerio JE, Robertson SJ, Bernardis C, Diem A, Fine JD, George R, et al. Management of cutaneous squamous cell carcinoma in patients with epidermolysis bullosa: best clinical practice guidelines. Br J Dermatol. 2016;174(1):56\u201367.","journal-title":"Br J Dermatol"},{"issue":"1","key":"3190_CR8","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1186\/s13023-016-0489-9","volume":"11","author":"H Montaudi\u00e9","year":"2016","unstructured":"Montaudi\u00e9 H, Chiaverini C, Sbidian E, Charlesworth A, Lacour J-P. Inherited epidermolysis bullosa and squamous cell carcinoma: a systematic review of 117 cases. Orphanet J Rare Dis. 2016;11(1):117.","journal-title":"Orphanet J Rare Dis"},{"issue":"8","key":"3190_CR9","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.3390\/cells11081365","volume":"11","author":"D Bonamonte","year":"2022","unstructured":"Bonamonte D, Filoni A, De Marco A, Lospalluti L, Nacchiero E, Ronghi V, et al. Squamous cell carcinoma in patients with inherited epidermolysis bullosa: Review of current literature. Cells. 2022;11(8):1365.","journal-title":"Cells"},{"issue":"Pt 11","key":"3190_CR10","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1242\/jcs.042895","volume":"122","author":"VL Martins","year":"2009","unstructured":"Martins VL, Vyas JJ, Chen M, Purdie K, Mein CA, South AP, et al. Increased invasive behaviour in cutaneous squamous cell carcinoma with loss of basement-membrane type VII collagen. J Cell Sci. 2009;122(Pt 11):1788\u201399.","journal-title":"J Cell Sci"},{"issue":"3","key":"3190_CR11","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1111\/j.1365-2559.1992.tb00962.x","volume":"20","author":"SD Slater","year":"1992","unstructured":"Slater SD, McGrath JA, Hobbs C, Eady RA, McKee PH. Expression of mutant p53 gene in squamous carcinoma arising in patients with recessive dystrophic epidermolysis bullosa. Histopathology. 1992;20(3):237\u201341.","journal-title":"Histopathology"},{"issue":"4","key":"3190_CR12","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1111\/j.0022-202X.2004.23418.x","volume":"123","author":"JL Arbiser","year":"2004","unstructured":"Arbiser JL, Fan C-Y, Su X, Van Emburgh BO, Cerimele F, Miller MS, et al. Involvement of p53 and p16 tumor suppressor genes in recessive dystrophic epidermolysis bullosa-associated squamous cell carcinoma. J Invest Dermatol. 2004;123(4):788\u201390.","journal-title":"J Invest Dermatol"},{"issue":"6","key":"3190_CR13","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1016\/j.jid.2017.12.026","volume":"138","author":"L Sans-DeSanNicolas","year":"2018","unstructured":"Sans-DeSanNicolas L, Carat\u00fa G, Vidal-Cort\u00e9s O, Sanchez-Redondo S, Ferrer B, Mancuso F, et al. Genetic Profiles of Squamous Cell Carcinomas Associated with Recessive Dystrophic Epidermolysis Bullosa Unveil NOTCH and TP53 Mutations and an Increased MYC Expression. J Invest Dermatol. 2018;138(6):1423\u20137.","journal-title":"J Invest Dermatol"},{"issue":"2","key":"3190_CR14","first-page":"213","volume":"12","author":"A Filoni","year":"2022","unstructured":"Filoni A, Cicco G, Cazzato G, Bosco A, Lospalluti L, Tucci M, et al. Immune Disregulation in Cutaneous Squamous Cell Carcinoma of Patients with Recessive Dystrophic Epidermolysis Bullosa: A Single Pilot Study. Life (Basel, Switzerland). 2022;12(2):213.","journal-title":"Life (Basel, Switzerland)"},{"issue":"1","key":"3190_CR15","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1159\/000218714","volume":"219","author":"AW Arnold","year":"2009","unstructured":"Arnold AW, Bruckner-Tuderman L, Zuger C, Itin PH. Cetuximab therapy of metastasizing cutaneous squamous cell carcinoma in a patient with severe recessive dystrophic epidermolysis bullosa. Dermatology. 2009;219(1):80\u20133.","journal-title":"Dermatology"},{"issue":"12","key":"3190_CR16","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1200\/JCO.2009.21.9170","volume":"27","author":"CJ Allegra","year":"2009","unstructured":"Allegra CJ, Jessup JM, Somerfield MR, Hamilton SR, Hammond EH, Hayes DF, et al. American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol. 2009;27(12):2091\u20136.","journal-title":"J Clin Oncol"},{"issue":"1","key":"3190_CR17","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1111\/bjd.12272","volume":"169","author":"M Kim","year":"2013","unstructured":"Kim M, Li M, Intong LRA, Tran K, Melbourne W, Marucci D, et al. Use of cetuximab as an adjuvant agent to radiotherapy and surgery in recessive dystrophic epidermolysis bullosa with squamous cell carcinoma. Br J Dermatol. 2013;169(1):208\u201310.","journal-title":"Br J Dermatol"},{"issue":"1","key":"3190_CR18","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1186\/s13023-019-1262-7","volume":"14","author":"A Diociaiuti","year":"2019","unstructured":"Diociaiuti A, Steinke H, Nystr\u00f6m A, Schwieger-Briel A, Meiss F, Pfannenberg C, et al. EGFR inhibition for metastasized cutaneous squamous cell carcinoma in dystrophic epidermolysis bullosa. Orphanet J Rare Dis. 2019;14(1):278.","journal-title":"Orphanet J Rare Dis"},{"issue":"4","key":"3190_CR19","first-page":"448","volume":"17","author":"K Medek","year":"2019","unstructured":"Medek K, Koelblinger P, Koller J, Diem A, Ude-Schoder K, Bauer JW, et al. Wound healing deficits in severe generalized recessive dystrophic epidermolysis bullosa along anticancer treatment with cetuximab. J Dtsch Dermatol Ges. 2019;17(4):448\u201350.","journal-title":"J Dtsch Dermatol Ges"},{"issue":"6","key":"3190_CR20","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1001\/jamadermatol.2020.0304","volume":"156","author":"A Piccerillo","year":"2020","unstructured":"Piccerillo A, El Hachem M, De Vito R, De Luca EV, Peris K. Pembrolizumab for Treatment of a Patient With Multiple Cutaneous Squamous Cell Carcinomas and Recessive Dystrophic Epidermolysis Bullosa. JAMA Dermatol. 2020;156(6):708\u201310.","journal-title":"JAMA Dermatol"},{"issue":"1","key":"3190_CR21","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1111\/jdv.15835","volume":"34","author":"A Reimer","year":"2020","unstructured":"Reimer A, Lu S, He Y, Bruckner-Tuderman L, Technau-Hafsi K, Meiss F, et al. Combined anti-inflammatory and low-dose antiproliferative therapy for squamous cell carcinomas in recessive dystrophic epidermolysis bullosa. J Eur Acad Dermatol Venereol. 2020;34(1):e1-3.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"3190_CR22","doi-asserted-by":"publisher","unstructured":"Duong T, Wong D, Barrett A, Price H. Successful use of immunotherapy to treat advanced cutaneous squamous cell carcinoma in recessive dystrophic epidermolysis bullosa. BMJ Case Rep. 2021; https:\/\/doi.org\/10.1136\/bcr-2020-238966.","DOI":"10.1136\/bcr-2020-238966"},{"issue":"3","key":"3190_CR23","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1111\/bjd.18095","volume":"182","author":"P Riihil\u00e4","year":"2020","unstructured":"Riihil\u00e4 P, Viiklepp K, Nissinen L, Farshchian M, Kallajoki M, Kivisaari A, et al. Tumour-cell-derived complement components C1r and C1s promote growth of cutaneous squamous cell carcinoma. Br J Dermatol. 2020;182(3):658\u201370.","journal-title":"Br J Dermatol"},{"issue":"5","key":"3190_CR24","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1016\/j.jid.2017.11.022","volume":"138","author":"Y Sun","year":"2018","unstructured":"Sun Y, Woess K, Kienzl M, Leb-Reichl VM, Feinle A, Wimmer M, et al. Extracellular Vesicles as Biomarkers for the Detection of a Tumor Marker Gene in Epidermolysis Bullosa-Associated Squamous Cell Carcinoma. J Invest Dermatol. 2018;138(5):1197\u2013200.","journal-title":"J Invest Dermatol"},{"key":"3190_CR25","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1080\/000155501750376285","volume":"81","author":"F Weber","year":"2001","unstructured":"Weber F, Bauer JW, Sepp N, Hogler W, Salmhofer W, Fritsch HHP. Squamous Cell Carcinoma in Junctional and Dystrophic Epidermolysis Bullosa. Acta Der m Venereo l. 2001;81:189\u201392.","journal-title":"Acta Der m Venereo l"},{"issue":"8","key":"3190_CR26","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1054\/bjps.2002.3955","volume":"55","author":"GA Georgeu","year":"2002","unstructured":"Georgeu GA, Ramsey KWD, El-Muttardi N, Mayou BJ. Groin dissections in epidermolysis bullosa: a report of groin dissection for the control of metastatic squamous carcinoma in patients with epidermolysis bullosa. Br J Plast Surg. 2002;55(8):678\u201382.","journal-title":"Br J Plast Surg"},{"key":"3190_CR27","unstructured":"O\u2019Sullivan GM, Clapham J, Mackenzie C, et al. Electrochemotherapy for metastatic squamous cell carcinoma in epidermolysis bullosa [abstract]. Acta Drem Venereol. 2020 100:SUPPL 220(40\u201341)."},{"issue":"8","key":"3190_CR28","doi-asserted-by":"publisher","first-page":"adv00523","DOI":"10.2340\/00015555-3875","volume":"101","author":"SJ Robertson","year":"2021","unstructured":"Robertson SJ, Orrin E, Lakhan MK, O\u2019Sullivan G, Felton J, Robson A, et al. Cutaneous Squamous Cell Carcinoma in Epidermolysis Bullosa: a 28-year Retrospective Study. Acta Derm Venereol. 2021;101(8):adv00523.","journal-title":"Acta Derm Venereol"},{"issue":"6","key":"3190_CR29","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1111\/j.1346-8138.2008.00479.x","volume":"35","author":"A Rokunohe","year":"2008","unstructured":"Rokunohe A, Nakano H, Aizu T, Kaneko T, Nakajima K, Ikenaga S, et al. Significance of sentinel node biopsy in the management of squamous cell carcinoma arising from recessive dystrophic epidermolysis bullosa. J Dermatol. 2008;35(6):336\u201340.","journal-title":"J Dermatol"},{"issue":"11","key":"3190_CR30","first-page":"1424","volume":"30","author":"M Yamada","year":"2004","unstructured":"Yamada M, Hatta N, Sogo K, Komura K, Hamaguchi Y, Takehara K. Management of squamous cell carcinoma in a patient with recessive-type epidermolysis bullosa dystrophica. Dermatol Surg. 2004;30(11):1424\u20139.","journal-title":"Dermatol Surg"},{"issue":"1","key":"3190_CR31","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1001\/archderm.141.1.110","volume":"141","author":"L Perez-Naranjo","year":"2005","unstructured":"Perez-Naranjo L, Herrera-Saval A, Garcia-Bravo B, Perez-Bernal AM, Camacho F. Sentinel lymph node biopsy in recessive dystrophic epidermolysis bullosa and squamous cell carcinoma. Arch Dermatol. 2005;141(1):110\u20131.","journal-title":"Arch Dermatol"},{"issue":"4","key":"3190_CR32","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1111\/j.1468-3083.2006.01938.x","volume":"21","author":"A S\u00fcss","year":"2007","unstructured":"S\u00fcss A, Sticherling M, Volz A, Frank R, Rudolph K-D, Simon JC. Large metastasizing squamous cell carcinoma in epidermolysis bullosa dystrophica Hallopeau-Siemens. J Eur Acad Dermatol Venereol. 2007;21(4):539\u201341.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"8","key":"3190_CR33","doi-asserted-by":"publisher","first-page":"omaa059","DOI":"10.1093\/omcr\/omaa059","volume":"2020","author":"J Lopes","year":"2020","unstructured":"Lopes J, Baptista A, Moreira A. Squamous cell carcinoma in a pregnant woman with recessive dystrophic epidermolysis bullosa. Oxf Med Case Reports. 2020;2020(8):omaa059.","journal-title":"Oxf Med Case Reports"},{"key":"3190_CR34","unstructured":"O\u2019Sullivan GM, Clapham J, Mackenzie C, et al. Cemiplimab for metastatic squamous cell carcinoma in epidermolysis bullosa [abstract]. Acta Derm Venereol. 2020 100:SUPPL 220(40)."},{"issue":"12","key":"3190_CR35","first-page":"1166","volume":"99","author":"A Saito","year":"2019","unstructured":"Saito A, Nakamura Y, Tanaka R, Inoue S, Okiyama N, Ishitsuka Y, et al. Unusual Bone Lesions with Osteonecrosis Mimicking Bone Metastasis of Squamous Cell Carcinoma in Recessive Dystrophic Epidermolysis Bullosa. Acta Derm Venereol. 2019;99(12):1166\u20139.","journal-title":"Acta Derm Venereol"},{"issue":"3","key":"3190_CR36","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1297\/cpe.20.65","volume":"20","author":"K Miura","year":"2011","unstructured":"Miura K, Umegaki N, Kitaoka T, Kubota T, Namba N, Etani Y, et al. A Male Patient with Humoral Hypercalcemia of Malignancy (HHM) with Leukocytosis Caused by Cutaneous Squamous Cell Carcinoma Resulting from Recessive Dystrophic Epidermolysis Bullosa. Clin Pediatr Endocrinol. 2011;20(3):65\u201371.","journal-title":"Clin Pediatr Endocrinol"},{"issue":"6","key":"3190_CR37","first-page":"1276","volume":"66","author":"SR Lentz","year":"1990","unstructured":"Lentz SR, Raish RJ, Orlowski EP, Marion JM. Squamous cell carcinoma in epidermolysis bullosa. Treatment with systemic chemotherapy Cancer. 1990;66(6):1276\u20138.","journal-title":"Treatment with systemic chemotherapy Cancer"},{"issue":"7","key":"3190_CR38","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1111\/j.1365-4632.2009.03910.x","volume":"48","author":"KN Shivaswamy","year":"2009","unstructured":"Shivaswamy KN, Sumathy TK, Shyamprasad AL, Ranganathan C. Squamous cell carcinoma complicating epidermolysis bullosa in a 6-year-old girl. Int J Dermatol. 2009;48(7):731\u20133.","journal-title":"Int J Dermatol"},{"issue":"5","key":"3190_CR39","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1046\/j.1365-2133.2003.05270.x","volume":"148","author":"H Kawasaki","year":"2003","unstructured":"Kawasaki H, Sawamura D, Iwao F, Kikuchi T, Nakamura H, Okubo S, et al. Squamous cell carcinoma developing in a 12-year-old boy with nonHallopeau-Siemens recessive dystrophic epidermolysis bullosa. Br J Dermatol. 2003;148(5):1047\u201350.","journal-title":"Br J Dermatol"},{"issue":"5","key":"3190_CR40","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1046\/j.1525-1470.2002.00202.x","volume":"19","author":"T Ayman","year":"2002","unstructured":"Ayman T, Yerebakan O, Cift\u00e7ioglu MA, Alpsoy E. A 13-year-old girl with recessive dystrophic epidermolysis bullosa presenting with squamous cell carcinoma. Pediatr Dermatol. 2002;19(5):436\u20138.","journal-title":"Pediatr Dermatol"},{"issue":"3","key":"3190_CR41","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1159\/000330331","volume":"223","author":"N Cuadrado-Corrales","year":"2011","unstructured":"Cuadrado-Corrales N, S\u00e1nchez-Jimeno C, Garc\u00eda M, Ayuso C, De Lucas R, Vicario JL, et al. A recurrent nonsense mutation occurring as a de novo event in a patient with recessive dystrophic epidermolysis bullosa. Dermatology. 2011;223(3):219\u201321.","journal-title":"Dermatology"},{"issue":"9","key":"3190_CR42","doi-asserted-by":"publisher","first-page":"E418","DOI":"10.1177\/000313481207800915","volume":"78","author":"CA Larocca","year":"2012","unstructured":"Larocca CA, Cordova AC, Price LA, Milner SM. Squamous cell carcinoma as a complication of epidermolysis bullosa. Am Surg. 2012;78(9):E418\u20139.","journal-title":"Am Surg"},{"issue":"6","key":"3190_CR43","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1111\/j.1365-4632.2009.04006.x","volume":"48","author":"A Dammak","year":"2009","unstructured":"Dammak A, Zribi J, Boudaya S, Mseddi M, Meziou TJ, Masmoudi A, et al. Squamous cell carcinoma complicating recessive dystrophic epidermolysis bullosa-Hallopeau-Siemens: a report of four cases. Int J Dermatol. 2009;48(6):588\u201391.","journal-title":"Int J Dermatol"},{"issue":"1","key":"3190_CR44","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1097\/00042728-200601000-00029","volume":"32","author":"A Saxena","year":"2006","unstructured":"Saxena A, Lee JB, Humphreys TR. Mohs micrographic surgery for squamous cell carcinoma associated with epidermolysis bullosa. Dermatol Surg. 2006;32(1):128\u201334.","journal-title":"Dermatol Surg"},{"issue":"4","key":"3190_CR45","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1159\/000246438","volume":"192","author":"A Van Rengen","year":"1996","unstructured":"Van Rengen A, Degreef H. Epidermolysis bullosa dystrophica of Hallopeau-Siemens and squamous-cell carcinoma: a case report. Dermatology. 1996;192(4):418\u20139.","journal-title":"Dermatology"},{"issue":"3","key":"3190_CR46","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1111\/j.1468-3083.1999.tb00883.x","volume":"13","author":"RJ Bosch","year":"1999","unstructured":"Bosch RJ, Gallardo MA, Ruiz del Portal G, Snchez P, Arce MF, Herrera E. Squamous cell carcinoma secondary to recessive dystrophic epidermolysis bullosa: report of eight tumours in four patients. J Eur Acad Dermatol Venereol. 1999;13(3):198\u2013204.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"3190_CR47","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1001\/archderm.1970.04000100022006","volume":"102","author":"HL Wechsler","year":"1970","unstructured":"Wechsler HL, Krugh FJ, Domonkos AN, Scheen SR, Davidson CL Jr. Polydysplastic epidermolysis bullosa and development of epidermal neoplasms. Arch Dermatol. 1970;102(4):374\u201380.","journal-title":"Arch Dermatol"},{"issue":"5","key":"3190_CR48","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/S0305-7372(03)00073-2","volume":"29","author":"A Gothelf","year":"2003","unstructured":"Gothelf A, Mir LM, Gehl J. Electrochemotherapy: results of cancer treatment using enhanced delivery of bleomycin by electroporation. Cancer Treat Rev. 2003;29(5):371\u201387.","journal-title":"Cancer Treat Rev"},{"issue":"6","key":"3190_CR49","doi-asserted-by":"publisher","DOI":"10.1111\/dth.14093","volume":"33","author":"J Bartolo","year":"2020","unstructured":"Bartolo J, Farricha V, Carvalhal S, Moura C, Abecasis N. Electrochemotherapy, a local treatment for squamous cell carcinoma in patients with recessive dystrophic epidermolysis bullosa. Dermatol Ther. 2020;33(6): e14093.","journal-title":"Dermatol Ther"},{"issue":"7","key":"3190_CR50","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1111\/jdv.13116","volume":"30","author":"A Diociaiuti","year":"2016","unstructured":"Diociaiuti A, Rotunno R, El Hachem M, Latorre S, Cozza R, Curatolo P. Electrochemotherapy, a potential new treatment for the management of squamous cell carcinoma in patients with recessive dystrophic epidermolysis bullosa: report of three cases. J Eur Acad Dermatol Venereol. 2016;30(7):1195\u20136.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"3190_CR51","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1159\/000248539","volume":"177","author":"M Keefe","year":"1988","unstructured":"Keefe M, Wakeel RA, Dick DC. Death from metastatic, cutaneous, squamous cell carcinoma in autosomal recessive dystrophic epidermolysis bullosa despite permanent inpatient care. Dermatologica. 1988;177(3):180\u20134.","journal-title":"Dermatologica"},{"issue":"4","key":"3190_CR52","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1159\/000247803","volume":"182","author":"JA McGrath","year":"1991","unstructured":"McGrath JA, Schofield OM, Mayou BJ, McKee PH, Eady RA. Metastatic squamous cell carcinoma resembling angiosarcoma complicating dystrophic epidermolysis bullosa. Dermatologica. 1991;182(4):235\u20138.","journal-title":"Dermatologica"},{"issue":"3","key":"3190_CR53","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1111\/j.1365-2133.2005.06783.x","volume":"153","author":"CS Souza","year":"2005","unstructured":"Souza CS, Fel\u00edcio LBA, Bentley MV, Tedesco AC, Ferreira J, Kurachi C, et al. Topical photodynamic therapy for Bowen\u2019s disease of the digit in epidermolysis bullosa. Br J Dermatol. 2005;153(3):672\u20134.","journal-title":"Br J Dermatol"},{"issue":"2","key":"3190_CR54","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1159\/000508933","volume":"13","author":"K Khaddour","year":"2020","unstructured":"Khaddour K, Gorell ES, Dehdashti F, Tang JY, Ansstas G. Induced Remission of Metastatic Squamous Cell Carcinoma with an Immune Checkpoint Inhibitor in a Patient with Recessive Dystrophic Epidermolysis Bullosa. Case Rep Oncol. 2020;13(2):911\u20135.","journal-title":"Case Rep Oncol"},{"key":"3190_CR55","doi-asserted-by":"publisher","first-page":"adv4870","DOI":"10.2340\/actadv.v103.4870","volume":"103","author":"L Trefzer","year":"2023","unstructured":"Trefzer L, Hess ME, Scholten L, et al. Variable Outcome of Immunotherapy in Advanced Multiple Cutaneous Squamous Cell Carcinomas in Two Patients with Recessive Dystrophic Epidermolysis Bullosa. Acta Derm Venereol. 2023;103:adv4870.","journal-title":"Acta Derm Venereol"},{"issue":"3","key":"3190_CR56","first-page":"295","volume":"21","author":"P Vasilev","year":"2023","unstructured":"Vasilev P, Kalev D, Karamanliev M, Dimitrov D, Troyanova P, Yordanova I. Cemiplimab treatment of squamous cell carcinoma in a patient with severe recessive dystrophic epidermolysis bullosa. J Dtsch Dermatol Ges. 2023;21(3):295\u20137.","journal-title":"J Dtsch Dermatol Ges"},{"issue":"SUPPL 220","key":"3190_CR57","first-page":"19","volume":"100","author":"A Bruckner","year":"2020","unstructured":"Bruckner A. Case report: A woman with rdeb and metastatic SCC managed with nivolumab. Acta Derm Venereol. 2020;100(SUPPL 220):19.","journal-title":"Acta Derm Venereol"},{"key":"3190_CR58","unstructured":"Nikbakht N. Rigosertib in Patients With Recessive Dystrophic Epidermolysis Bullosa Associated SCC. ClinicalTrials.gov identifier: NCT04177498. Updated September 8, 2022. [cited 2023 May 27]. Available from:\u00a0https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04177498."},{"key":"3190_CR59","unstructured":"Bauer J. Rigosertib for RDEB-SCC. ClinicalTrials.gov identifier: NCT03786237. Updated November 4, 2022. [cited 2023 May 27]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03786237."},{"issue":"11","key":"3190_CR60","doi-asserted-by":"publisher","first-page":"3384","DOI":"10.1158\/1078-0432.CCR-18-2661","volume":"25","author":"VS Atanasova","year":"2019","unstructured":"Atanasova VS, Pourreyron C, Farshchian M, et al. Identification of Rigosertib for the Treatment of Recessive Dystrophic Epidermolysis Bullosa-Associated Squamous Cell Carcinoma. Clin Cancer Res. 2019;25(11):3384\u201391.","journal-title":"Clin Cancer Res"},{"issue":"14","key":"3190_CR61","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1200\/JCO.2016.70.1524","volume":"35","author":"J Bauml","year":"2017","unstructured":"Bauml J, Seiwert TY, Pfister DG, Worden F, Liu SV, Gilbert J, et al. Pembrolizumab for platinum- and cetuximab-refractory head and neck cancer: Results from a single-arm, phase II study. J Clin Oncol. 2017;35(14):1542\u20139.","journal-title":"J Clin Oncol"},{"issue":"17","key":"3190_CR62","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1056\/NEJMoa2209813","volume":"387","author":"ND Gross","year":"2022","unstructured":"Gross ND, Miller DM, Khushalani NI, Divi V, Ruiz ES, Lipson EJ, et al. Neoadjuvant cemiplimab for stage II to IV cutaneous squamous-cell carcinoma. N Engl J Med. 2022;387(17):1557\u201368.","journal-title":"N Engl J Med"},{"key":"3190_CR63","doi-asserted-by":"publisher","DOI":"10.1186\/s13643-016-0384-4","author":"M Ouzzani","year":"2016","unstructured":"Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan \u2014 a web and mobile app for systematic reviews. Syst Rev. 2016. https:\/\/doi.org\/10.1186\/s13643-016-0384-4.","journal-title":"Syst Rev."},{"key":"3190_CR64","unstructured":"Joanna Briggs Institute. Critical Appraisal Tools [Internet]. Adelaide (AU): Joanna Briggs Institute; [cited 2024 Feb 19]. JBI. 2020. Available from: https:\/\/jbi.global\/critical-appraisal-tools."},{"key":"3190_CR65","unstructured":"The Cochrane Collaboration. Cochrane Risk-of-Bias Tool for Randomized Trials (RoB 2) [Internet]. [place unknown]: The Cochrane Collaboration; [cited 2024 Feb 19]. Available from: https:\/\/sites.google.com\/site\/riskofbiastool\/welcome\/rob-2-0-tool?authuser=0&pli=1."},{"key":"3190_CR66","unstructured":"U.S. Department of Health and Human Services National Toxicology Program. OHAT Risk of Bias Tool [Internet]. Maryland (US): U.S. Department of Health and Human Services National Toxicology Program; [cited 2024 Feb 19]. Available from: https:\/\/ntp.niehs.nih.gov\/whatwestudy\/assessments\/noncancer\/riskbias\/index.html."}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-024-03190-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-024-03190-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-024-03190-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,21]],"date-time":"2024-05-21T03:33:34Z","timestamp":1716262414000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-024-03190-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,21]]},"references-count":66,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3190"],"URL":"https:\/\/doi.org\/10.1186\/s13023-024-03190-1","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,21]]},"assertion":[{"value":"3 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"ASP is an Investigator for AbbVie, Applied Pharma Research, Dermavant, Eli Lilly, Incyte, Janssen, Krystal, Regeneron, UCB; Consultant for Aegerion Pharma, Azitra, BioCryst, Boehringer-Ingelheim, Bristol Myers Squibb, Eli Lilly, Janssen, Johnson & Johnson, Krystal, LEO Pharma, Novartis, Primus, Regeneron, Sanofi\/Genzyme, Seanergy, TWI Biotechnology, UCB; and Data Safety Monitoring Board for AbbVie, Abeona, Catawba, Galderma, InMed.None of the other authors report conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"206"}}